U045 Field Cancerization Therapies: Medical Dermatology and Beyond
DESCRIPTION
Field cancerization theory postulates that the skin surrounding actinic keratoses (AKs) is at increased risk for possible precancerous changes and malignant transformation. Field-directed therapies have the potential to target clinically evident and sub-clinically damaged skin, reduce AK recurrences, and further reduce NMSC risk and particularly SCCs, in elderly and chronically immunosuppressed patients. This session will outline the standard of care field therapies including and not limited to topical 5- fluorouracil, imiquimod, conventional/daylight photodynamic therapy, lasers, peels and other modalities. Clinical algorithms, outcomes and potency of field therapies as monotherapies or in combination, will be evaluated.
LEARNING OBJECTIVES
Define the concept of field cancerization.
Outline standard of care field therapies for AKs and NMSC, applied as monotherapies or in combination.
Select the right candidates for field directed therapies and for a variety of cutaneous entities.
SCHEDULE
4:30 PM
Field Cancerization Therapies: Medical Dermatology and Beyond
DIRECTOR
Maria M. Tsoukas, MD, PhD, FAAD
SPEAKERS
Nellie Konnikov, MD, FAAD
Rolf-Markus Szeimies, MD, PhD, IFAAD
DISCLOSURES
Nellie Konnikov, MD, FAAD
No financial relationships exist with ineligible companies.
Rolf-Markus Szeimies, MD, PhD, IFAAD
AbbVie – Speaker(Honoraria); Almirall – Advisory Board(Honoraria), Speaker(Honoraria); Beiersdorf, Inc. – Advisory Board(Fees); Biofrontera AG – Investigator(Fees), Speaker(Honoraria); Eli Lilly – Speaker(Honoraria); Galderma Laboratories, L.P. – Advisory Board(Honoraria), Investigator(Fees), Speaker(Honoraria); Janssen Pharmaceuticals, Inc – Speaker(Honoraria); Kurt Wolff GmbH & Co. KG – Advisory Board(Fees), Investigator(Fees); Leo Pharma A/S – Advisory Board(Honoraria), Investigator(Fees); Springer Publishing – Advisory Board(Honoraria);
Maria M. Tsoukas, MD, PhD, FAAD
No financial relationships exist with ineligible companies.